Biller Scott 4

What Happened
Scott Biller, a director of Foghorn Therapeutics, was granted a derivative award on 2026-06-24 that covers 28,000 shares with a strike/equivalent price of $4.08 per share, representing a notional value of $114,240. This filing records the grant (award/acquisition of a derivative) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-25 (timely filing).
• Award: 28,000 derivative shares at $4.08 per share; total notional value $114,240.
• Type: Derivative grant (option award) — not an immediate stock purchase or sale.
• Vesting: Per footnote F1, the option vests in full on the first anniversary of the grant date, subject to continued board service.
• Shares owned after transaction: not specified in the provided excerpt.

Context
This was an option/award grant to a board member, which becomes exercisable only after vesting (one year subject to service). Because it is a derivative grant (not an open-market buy or sale), it does not reflect an immediate transfer of common shares or a cash transaction. Grants to directors are common compensation practices and are reported to show potential future insider ownership.